Arrowhead Pauses ARO-ENaC Study Amid Safety Concerns

Arrowhead Pauses ARO-ENaC Study Amid Safety Concerns

298462

Arrowhead Pauses ARO-ENaC Study Amid Safety Concerns

Arrowhead Pharmaceuticals has voluntarily paused new screening, enrollment, and dosing in its Phase 1/2 trial of ARO-ENaC, an investigational treatment for cystic fibrosis (CF). The decision came after unexpected signs of local lung inflammation occurred in an ongoing chronic toxicology study taking place in rats. “The safety of patients that participate in clinical trials of our investigational medicines is paramount to us at Arrowhead,” Javier San Martin, MD, the company’s chief medical officer, said in…

You must be logged in to read/download the full post.